Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia
A legfontosabb adatok
- Ki végzi
- Mahidol University
- Hol
- Bangkok (Thaiföld)A helyszín megnézése
- Azonosító
- Állapot
- Csak meghívásos
- Fázis
- 3. fázis
- Résztvevők
- 86 fő, tervezett
- Kezdés
- 2023. nov. 15.
- Tervezett befejezés
- 2026. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Branched-chain amino acid
- Placebo
- A regiszteradat frissítve
- 2025. szeptember 29.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with liver cirrhosis and low muscle mass (sarcopenia). They will take branched-chain amino acids or a placebo for 24 weeks.
- Életkor
- 18 to 85 years
- Nem
- All sexes
- A betegség stádiuma
- Liver cirrhosis from any cause. Low muscle mass shown on a CT scan in the last 3 months: Skeletal Muscle Index (SMI) less than 42 cm²/m² in males, less than 38 cm²/m² in females. People with Child-Turcotte-Pugh score C cannot join.
- Korábbi kezelés
- People who have had a liver or kidney transplant cannot join.
- Biomarker vagy leletérték
- Skeletal Muscle Index (SMI) on CT: less than 42 cm²/m² for males, less than 38 cm²/m² for females.
A részvétel fő kizáró okai
- Liver cancer (hepatocellular carcinoma) outside the Milan criteria
- Clear brain problems from liver disease (overt hepatic encephalopathy) or gut bleeding in the last 6 months
- Fluid in the belly that does not respond to treatment, or sudden liver failure on top of chronic disease (ACLF)
- Severe uncontrolled other illness, such as heart failure NYHA 3-4, kidney disease needing dialysis, Gold D lung disease, other cancers needing chemotherapy, or tuberculosis
- HIV infection, pregnancy or breastfeeding
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Patients aged between 18 and 85 years
- Patients who have been diagnosed with liver cirrhosis due to any etiology
- Patients with sarcopenia as determined by a computed tomography scan within the last 3 months. For males, sarcopenia is defined as a Skeletal Muscle Index (SMI) less than 42 cm²/m², and for females, an SMI less than 38 cm²/m²
Ki nem vehet részt
- Patients who have previously undergone liver or kidney transplantation
- Patients with Overt Hepatic Encephalopathy or gastrointestinal bleeding within the last 6 months
- Patients with acute-on-chronic liver failure (ACLF)
- Patients with uncontrollable decompensated comorbidities, including chronic heart failure classified as NYHA 3-4, patients with kidney disease requiring dialysis, patients with severe obstructive lung disease classified as Gold D, patients with other non-liver cancers requiring chemotherapy, and patients with chronic infections such as tuberculosis
- Patients with Human Immunodeficiency Virus (HIV) infection
- Patients with hepatocellular carcinoma outside the Milan criteria
- Patients with refractory ascites (ascites that does not respond to treatment)
- Patients in the advanced stage of cirrhosis with Child-Turcotte-Pugh (CTP) score C
- Pregnant or breastfeeding patients
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 85 év között vagy?
Helyszínek itt: Thaiföld
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandBangkok, ThaiföldCsak meghívásos
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to compare the nutritional parameters after 24-week supplementation of branched-chain amino acids in cirrhotic patients with low muscle mass.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
Is there the differences in the proportions of cirrhotic patients recovering from low muscle mass at 24 weeks among cirrhotic patients with low muscle mass who received BCAA supplementation and the placebo group? Is there the differences in the change of skeletal muscle index (SMI) measured by abdominal computed tomography (CT) at 24 weeks among cirrhotic patients with low muscle mass who received BCAA supplementation and the placebo group? Is there changes in other indices related to low muscle mass, including appendicular skeletal muscle mass (ASM), ASM/height\^2, handgrip strength, and 6-meter walk speed at 24 weeks among cirrhotic patients with low muscle mass who received BCAA supplementation and the placebo group? Is there changes in the liver frailty index (LFI), consisting of handgrip strength, chair stands, and balance, at 24 weeks among cirrhotic patients with low muscle mass who received BCAA supplementation and the placebo group? Is there changes in serum albumin levels, at 24 weeks among cirrhotic patients with low muscle mass who received BCAA supplementation and the placebo group? Is there changes in severity of liver disease, including the Model for End-Stage Liver Disease-Sodium Score (MELD-Na score), Child-Turcotte-Pugh score, and liver stiffness measured by transient elastography at 24 weeks among cirrhotic patients with low muscle mass who received BCAA supplementation and the placebo group?
Participants will be asked to do following tasks:
Participants will be asked for basic information such as age, place of residence, and contact phone number.
Participants will undergo measurements of body weight, height, body mass index (BMI), muscle mass, and body fat content using a body composition analyzer, a total of 2 times (at the beginning and end of the research), and an upper abdominal computed tomography (CT) scan without additional radiation exposure, only once (at the end of the research) throughout the study.
Participants will be tested for muscle function, including handgrip strength, a 6-meter walk test, chair stands, and balance, all performed twice (at the beginning and end of the research).
Laboratory testing will include a complete blood count, liver and kidney function, blood clotting function, mineral levels, cholesterol, and glucose. Blood will be drawn a total of 2 times (at the beginning and end of the research) during the study, with each blood draw approximately 15 milliliters (1 tablespoon).
Transient elastography will be performed twice (at the beginning and end of the research) during the study, with each Transient elastography taking approximately 10 minutes.
Participants will be randomly assigned to either the group receiving branched chain amino acid (BCAA) medication or the placebo group, and you will take the assigned medication twice daily for a total of 24 weeks.
Participants will receive dietary and exercise recommendations from the research team and nutritionists in a group format, taking approximately 1 hour.
Participants will have follow-up appointments to monitor your condition three times during the study, at weeks 4, 12, and 24. These appointments will include inquiries about side effects from medication and placebo use, exercise, and dietary intake, each lasting approximately 30 minutes.
Participants will be asked to take photos of your daily meals for 3 days before meeting with the physician at weeks 4 and 12, to provide data for assessing your calorie intake. Participants can send these meal images via the online application, prepared by our research team. If participants are unable to do so, participants will be asked to keep a food diary and report your food and portion sizes to the research team.
A vizsgálat 2 csoportja
- Branched-chain amino acidA vizsgált kezelés
In the branched-chain amino acid (BCAA group), participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
- PlaceboPlacebo, összehasonlításként
In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia: a Double-blinded Randomized Controlled Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06121492: ki vehet részt
- A regiszteradat frissítve
- 2025. szeptember 29.